INNOVENT'S PARTNER OLLIN BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA WITH SUPERIOR OUTCOMES FROM A RANDOMIZED HEAD-TO-HEAD STUDY OF IBI324 COMPARED TO FARICIMAB (VABYSMO®) IN DIABETIC MACULAR EDEMA AND WET AGE-RELATED MACULAR DEGENERATION

Reuters · 3d ago

Please log in to view news